|
|
The
Simon Foundation for Continence |
| Innovating
Conference
Endorsing Organizations... International Continence Society Retirement Research Foundation Society of Urologic Nurses and Associates Women's Health Foundation The Women's Sexual Health Foundation Gold Sponsor...
Silver Sponsors...
Workshop Sponsors... What do incontinence pad users want from their products? The Science of Creativity Contributors $500-$999 $1,000-$2,499 $2,500-$4,999 $5,000-$7,499 |
2007 Conference: Innovating for Continence: The Engineering Challenge | |
 |
PLANNING COMMITTEE | |
|
Alan Cottenden, PhD Dr Alan Cottenden took a first degree in Materials Science
at CSTG work involves numerous collaborations with industry,
hospitals, incontinent user groups and universities and current projects
range from understanding the fundamental science of absorbency and of
incontinence-related skin health, through the development of
instrumentation for laboratory and clinical work, product development, and
the laboratory and clinical evaluation of existing and prototype products,
to work on incontinence-related quality of life and health economic
measures. Dr Cottenden has a particular interest in absorbent
products and a major thrust of recent years has been to develop predictive
models to facilitate the design of more effective products based on a
sound understanding of the interaction between urine and absorbent/porous
materials. Complementary work has aimed to establish links between the
clinical performance of pads (notably, leakage and wet comfort) and
laboratory data. Two large international projects have produced data upon
which international standards have been based and a recent study – which
established the (non) efficacy of various design features – is being
used by the UK NHS Purchasing and Supplies Agency as a basis for placing
national contracts with pad suppliers. Dr Cottenden has published widely in the clinical and
technical incontinence literature and recently headed up the international
team of writers producing the incontinence products chapter in the book
published from the third International Consultation on Incontinence
sponsored by the International Continence Society and the World Health
Organisation. He holds some 20 patents for incontinence product designs of
which the most successful is Kylie Pants, an aesthetically attractive
washable absorbent product for lightly incontinent people. He is on the Advisory Board of the Simon Foundation and a
Trustee of the UK Continence Foundation.
Cheryle B. Gartley is the founder and president of The
Simon Foundation for Continence, a
Born in Landed in Canadian citizen with a Resident of 1969 Completes commerce (business) studies at Employed in the healthcare industry since 1956. December 1967: Opens a repair shop in March 1969: Introduces Karl Storz endoscopes in October 1971: Sells repair business to give more time to
sales activities. May 1975: Karl Storz
K.G. Germany ask Laborie (company) to become their exclusive
distributor in 1977: Life Tech approach Laborie and within 12 months
become the number one supplier of urodynamics equipment in 1980: Laborie is approached by Pentax , MBB (lasers) and
Bruel and Kjaer to introduce their products in 1982: Because Disa (subsequently Dantec, then Medtronic)
had introduced a digital window to read uroflow values, Laborie, in trying
a way to apply the concept to all channels, realize that urodynamics can
be done with a simple computer: propose this at no cost to all
manufacturers of urodynamics equipment: they all refuse. 1984: Laborie introduce the first totally computerized
urodynamics system at AUA. 1985: Laborie, with a gynecologist in 1986: Laborie develops a colonoscope introducer. Develop
an inverting concept of their own. 1987: Following Ray’s Mother’s accident and ensuing
condition, Laborie decides to dedicate their future to finding better ways
to evaluate and treat urinary incontinence issues. Invest considerable
time and money into research. 1990: Urodynamics is made easier to do when Laborie
introduce Windows as operating system for its urodynamic analyzers. 1992: Laborie develops a device to measure pressure and
flow of blood into the corpus cavernosum using photo-pletysmography. 1995: Laborie closes their distribution company in 1998: Laborie purchases the stimulation-biofeedback
technology from a French manufacturer with the intention of modifying it
to meet the demands of the North American market.
Since then the device has been completely redone and enjoys great
success because of its animation software. 1998: Laborie presents a video at the ICI in Research and product developments continue. For two years
now, Laborie is the only manufacturer of urodynamics equipment using
wireless technology. I depend on engineers who work in the company to develop,
to perfect and to offer their ideas as well, not just mine. We also work
with universities but we cannot do that in the Note: This C.V. is in fact a C.V. of the company that is
made up of many individuals, some of great competence. Whatever has been
accomplished by this company is the result of a common effort by the
members of this company.
Monica Liebert, PhD, is currently the Director of Research
at the American Urological Association (AUA) Foundation.
The mission of the AUA Foundation Office of Research is to
“improve the care and treatment of patients with urological diseases
through enhanced urology research.”
Dr. Liebert joined the AUA from the National Institute for Diabetes
and Digestive and Kidney Diseases, National Institutes of Health, where
she served as Program Officer for the Urology Basic Sciences Program.
She has previously held faculty positions at The University of
Texas-M.D. Anderson Cancer Center in
Work Experience Hollister
Incorporated, a global medical device manufacturing/marketing company,
specializing in ostomy, wound, continence, mother/baby care and patient
identification/security products. 1982 -1984
Director of 1984 – 1995 Director
of International Marketing and Administrative Services 1995 - 2000 Group
Product Manager, Asia, Latin America, Middle East and 2001 – current Manager, Customer and Professional
Relations, Global Marketing Organization Baxter
International, a multinational company specializing in a broad range
of medical diagnostic, therapeutic and management products. 1976 - 1982 Director
of Product Planning, Renal Therapy (Dialysis) and Cardiopulmonary
(Heart-Lung) Systems IBM Corporation 1970 – 1976 Process
Control / Laboratory Automation Computer Systems Specialist Education Masters Business Administration (MBA), Master of Science Electrical Engineering (MSEE), Bachelor of Science Electrical Engineering (BSEE),
Christopher
K. Payne, M.D., FACS Christopher Payne grew up in Dr. Payne is nationally recognized as a leader on issues
in female urology having served on NIH advisory panels on urinary
incontinence and interstitial cystitis and a member of the panel which
defined bladder research priorities for the 21st century at a meeting
sponsored by the Office of Women’s Health Research.
He is a current member of the medical advisory board for the
Interstitial Cystitis Association. He
has published numerous articles and book chapters on urinary incontinence
and surgical reconstruction. He
has been an invited faculty member at both international and national
meetings and was invited to address the plenary session of the American
Urological Association meeting in 1998 and 2005.
His expertise in clinical research has been recognized through two
NIH principal investigator grants focusing on treatment of interstitial
cystitis and appointment as Chair of the Research Methodology subcommittee
for the World Health Organization’s International Consultation on
Incontinence. Dr. Payne’s practice is concentrated in three
areas—surgical treatment of urinary incontinence and pelvic prolapse,
clinical trials in interstitial cystitis and urinary incontinence, and
urodynamic evaluation of complex bladder dysfunction.
Clinical Interests Male and Female Urinary Incontinence Pelvic Prolapse Interstitial Cystitis Urinary Obstruction and Fistulas Minimally invasive treatment of male voiding dysfunction/BPH Current Research Projects Interstitial Cystitis NIH clinical trials group Different methods of anesthetizing the bladder in chronic
pain Use of iontophoresis to perform office bladder distention Novel method for sacral nerve stimulation
Karl
B. Thor,
PhD,
formed
Urogenix, Inc., as a subsidiary of Astellas Pharmaceuticals, Inc., in
March of 2007 and holds the position of vice-president of research.
In addition, Dr. Thor holds Adjunct Research Associate
Professor positions in the Department of Surgery/Division of Urology and
the Department of Obstetrics and Gynecology at Dr. Thor received his
PhD in Pharmacology from the University of Pittsburgh School of Medicine
where he trained under William (Chet) de Groat, Ph.D. and was supported by
a PhARMA predoctoral fellowship. He held a National Research Service Award
postdoctoral fellowship from the NIH at Dr.
Thor has published numerous articles and book chapters on CNS control of
lower urinary tract function and holds several patents for methods of
treating urinary bladder and sexual dysfunction. He is a member of the
Urodynamics Society, the International Continence Society, and the Society
for Neuroscience. He served as a member of the FDA-PhARMA Industry
Guidelines for Urinary Incontinence Trials in 1998. He has served as a
peer reviewer for the NIH on the Urology Special Emphasis Study Section,
the National Institutes of Neurological Disorders and Stroke Neurology B
Study Section, and the Small Business Initiative Review Study Section. He
has served on the World Health Organization’s International Consultation
on Incontinence since its inception. |
||
